BB&T Securities LLC grew its holdings in shares of Anika Therapeutics Inc. (NASDAQ:ANIK) by 29.7% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,266 shares of the biotechnology company’s stock after purchasing an additional 3,035 shares during the quarter. BB&T Securities LLC owned approximately 0.09% of Anika Therapeutics worth $769,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new stake in Anika Therapeutics in the 3rd quarter worth approximately $118,000. Municipal Employees Retirement System of Michigan increased its holdings in Anika Therapeutics by 3.0% in the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 3,450 shares of the biotechnology company’s stock worth $170,000 after acquiring an additional 100 shares in the last quarter. Victory Capital Management Inc. increased its holdings in Anika Therapeutics by 17.6% in the 2nd quarter. Victory Capital Management Inc. now owns 4,060 shares of the biotechnology company’s stock worth $200,000 after acquiring an additional 608 shares in the last quarter. BNP Paribas Arbitrage SA increased its holdings in Anika Therapeutics by 3.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 4,315 shares of the biotechnology company’s stock worth $213,000 after acquiring an additional 126 shares in the last quarter. Finally, Stevens Capital Management LP purchased a new stake in Anika Therapeutics in the 3rd quarter worth approximately $222,000. 84.87% of the stock is owned by hedge funds and other institutional investors.

In other Anika Therapeutics news, insider Richard Hague sold 5,250 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The stock was sold at an average price of $54.48, for a total value of $286,020.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Charles H. Sherwood sold 3,293 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $60.04, for a total value of $197,711.72. The disclosure for this sale can be found here. Insiders sold a total of 43,886 shares of company stock valued at $2,606,455 over the last 90 days. 6.57% of the stock is currently owned by corporate insiders.

Shares of Anika Therapeutics Inc. (ANIK) opened at $53.66 on Friday. The stock has a market cap of $786.75, a P/E ratio of 24.88, a P/E/G ratio of 2.78 and a beta of 1.46. Anika Therapeutics Inc. has a fifty-two week low of $41.64 and a fifty-two week high of $60.29.

Anika Therapeutics (NASDAQ:ANIK) last posted its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.46 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.05. Anika Therapeutics had a return on equity of 13.40% and a net margin of 28.23%. The business had revenue of $27.18 million during the quarter, compared to the consensus estimate of $27.44 million. During the same period in the prior year, the company posted $0.59 EPS. The firm’s revenue for the quarter was up 5.4% compared to the same quarter last year. analysts anticipate that Anika Therapeutics Inc. will post 1.9 EPS for the current year.

Separately, Barrington Research increased their target price on shares of Anika Therapeutics from $53.00 to $57.00 and gave the stock an “outperform” rating in a report on Friday, October 27th.

TRADEMARK VIOLATION WARNING: “BB&T Securities LLC Grows Stake in Anika Therapeutics Inc. (ANIK)” was reported by Watch List News and is owned by of Watch List News. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.watchlistnews.com/bbt-securities-llc-grows-stake-in-anika-therapeutics-inc-anik/1754948.html.

Anika Therapeutics Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company is engaged in developing, manufacturing and commercializing products based on its hyaluronic acid (HA) technology. The Company’s orthopedic medicine portfolio includes ORTHOVISC, MONOVISC, and CINGAL, which alleviate pain and restore joint function by replenishing depleted HA, and HYALOFAST, a solid HA-based scaffold to aid cartilage repair and regeneration.

Institutional Ownership by Quarter for Anika Therapeutics (NASDAQ:ANIK)

Receive News & Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.